Literature DB >> 31914875

What potential is there for LSD1 inhibitors to reach approval for AML?

Manu R Pandey1, Eunice S Wang1.   

Abstract

Entities:  

Keywords:  LSD1 inhibitor; acute myeloid leukemia; clinical trial; epigenetic

Mesh：

Substances：

Year:  2019        PMID： 31914875      PMCID： PMC7906834          DOI： 10.1080/14728214.2019.1694001

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN： 1472-8214            Impact factor:   4.191


× No keyword cloud information.
  36 in total

1.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

2.  DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression.

Authors:  Bruno Perillo; Maria Neve Ombra; Alessandra Bertoni; Concetta Cuozzo; Silvana Sacchetti; Annarita Sasso; Lorenzo Chiariotti; Antonio Malorni; Ciro Abbondanza; Enrico V Avvedimento
Journal:  Science       Date:  2008-01-11       Impact factor: 47.728

3.  LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.

Authors:  Jürgen Sonnemann; Miriam Zimmermann; Christian Marx; Franziska Ebert; Sabine Becker; Marie-Luise Lauterjung; James F Beck
Journal:  Br J Haematol       Date:  2017-12-03       Impact factor: 6.998

4.  A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.

Authors:  N Sugino; M Kawahara; G Tatsumi; A Kanai; H Matsui; R Yamamoto; Y Nagai; S Fujii; Y Shimazu; M Hishizawa; T Inaba; A Andoh; T Suzuki; A Takaori-Kondo
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

5.  A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.

Authors:  Yoshinori Ishikawa; Kanae Gamo; Masato Yabuki; Shinji Takagi; Kosei Toyoshima; Kazuhide Nakayama; Akiko Nakayama; Megumi Morimoto; Hitoshi Miyashita; Ryo Dairiki; Yukiko Hikichi; Naoki Tomita; Daisuke Tomita; Shinichi Imamura; Misa Iwatani; Yusuke Kamada; Satoru Matsumoto; Ryujiro Hara; Toshiyuki Nomura; Ken Tsuchida; Kazuhide Nakamura
Journal:  Mol Cancer Ther       Date:  2016-11-30       Impact factor: 6.261

6.  Lysine methylation regulates E2F1-induced cell death.

Authors:  Haroula Kontaki; Iannis Talianidis
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

7.  DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia.

Authors:  Annegret Glasow; Angela Barrett; Kevin Petrie; Rajeev Gupta; Manuel Boix-Chornet; Da-Cheng Zhou; David Grimwade; Robert Gallagher; Marieke von Lindern; Samuel Waxman; Tariq Enver; Guido Hildebrandt; Arthur Zelent
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

8.  The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation.

Authors:  Jing Wang; Sarah Hevi; Julia K Kurash; Hong Lei; Frédérique Gay; Jeffrey Bajko; Hui Su; Weitao Sun; Hua Chang; Guoliang Xu; François Gaudet; En Li; Taiping Chen
Journal:  Nat Genet       Date:  2008-12-21       Impact factor: 38.330

Review 9.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Authors:  Omar Abdel-Wahab; Ross L Levine
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

10.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Authors:  Wanqiang Sheng; Martin W LaFleur; Thao H Nguyen; Sujun Chen; Ankur Chakravarthy; Jake Ryan Conway; Ying Li; Hao Chen; Henry Yang; Pang-Hung Hsu; Eliezer M Van Allen; Gordon J Freeman; Daniel D De Carvalho; Housheng Hansen He; Arlene H Sharpe; Yang Shi
Journal:  Cell       Date:  2018-06-21       Impact factor: 41.582
View more
  1 in total

1.  Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.

Authors:  Warren Fiskus; Christopher P Mill; Behnam Nabet; Dimuthu Perera; Christine Birdwell; Taghi Manshouri; Bernardo Lara; Tapan M Kadia; Courtney DiNardo; Koichi Takahashi; Naval Daver; Prithviraj Bose; Lucia Masarova; Naveen Pemmaraju; Steven Kornblau; Gautam Borthakur; Guillermo Montalban-Bravo; Guillermo Garcia Manero; Sunil Sharma; Matthew Stubbs; Xiaoping Su; Michael R Green; Cristian Coarfa; Srdan Verstovsek; Joseph D Khoury; Christopher R Vakoc; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-05-20       Impact factor: 9.812
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.